Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Group 1 - Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs [1][3] - The company will host a webcast on March 17, 2025, at 4:30 p.m. Eastern Time to discuss its financial results and provide a business update for Q4 and the full year ended December 31, 2024 [1][2] - Belite's lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently undergoing multiple clinical trials, including Phase 3 studies [3]